help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paquot, N.
Right arrow Articles by Scheen, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paquot, N.
Right arrow Articles by Scheen, A. J.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 3 1316-1319
Copyright © 2000 by The Endocrine Society

Comments

No Increased Insulin Sensitivity after a Single Intravenous Administration of a Recombinant Human Tumor Necrosis Factor Receptor: Fc Fusion Protein in Obese Insulin-Resistant Patients1

Nicolas Paquot, Manuel J. Castillo, Pierre J. Lefèbvre and Andre J. Scheen

Division of Diabetes, Nutrition, and Metabolic Disorders, Department of Medicine, C.H.U. Sart- Tilman, B-4000 Liège, Belgium; and Clinical Physiology Unit, School of Medicine, University of Granada, Granada, Spain

Address correspondence and requests for reprints to: Prof. A. J. Scheen, Division of Diabetes, Nutrition, and Metabolic Disorders, Department of Medicine, C.H.U. Sart Tilman, B-4000 Liège 1, Belgium.

Abstract

Inhibition of tumor necrosis factor (TNF)-{alpha} results in a marked increase in insulin sensitivity in obese rodents. We investigated the influence of a TNF antagonist [Ro 45-2081, a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1] on insulin sensitivity of patients with android obesity. Seven patients (five women and two men; mean ± SD age, 41 ± 4 yr; body mass index, 36.1 ± 4.7 kg/m2; waist to hip ratio, 0.99 ± 0.11) were studied (three patients with normal glucose tolerance and four patients with impaired glucose tolerance or mild diabetes; all were hyperinsulinemic). Each patient underwent two consecutive euglycemic hyperinsulinemic glucose-clamp tests: 48 h after injection of placebo and 48 h after a single iv injection of 50 mg Ro 45-2081. In both tests, steady-state plasma glucose and insulin levels were similar. Insulin-mediated glucose disposal (2.23 ± 0.74 vs. 2.38 ± 0.99 mg/kg-1·min-1) and glucose metabolic clearance rate (2.28 ± 0.85 vs. 2.48 ± 1.03 mL/kg-1·min-1) were similar after placebo and after the drug. Indirect calorimetry showed no difference in substrate oxidation rates between the two experimental conditions. In conclusion, under the conditions of this study, no improvement in insulin sensitivity was observed in obese insulin-resistant patients following a single iv administration of a recombinant TNF receptor: Fc fusion protein.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
R. Zhang, E. Maratos-Flier, and J. S. Flier
Reduced Adiposity and High-Fat Diet-Induced Adipose Inflammation in Mice Deficient for Phosphodiesterase 4B
Endocrinology, July 1, 2009; 150(7): 3076 - 3082.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D.-E. Lee, S. Kehlenbrink, H. Lee, M. Hawkins, and J. S. Yudkin
Getting the message across: mechanisms of physiological cross talk by adipose tissue
Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1210 - E1229.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Maury, L. Noel, R. Detry, and S. M. Brichard
In Vitro Hyperresponsiveness to Tumor Necrosis Factor-{alpha} Contributes to Adipokine Dysregulation in Omental Adipocytes of Obese Subjects
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1393 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Liang, B. Yin, H. Zhang, S. Zhang, Q. Zeng, J. Wang, X. Jiang, L. Yuan, C.-Y. Wang, and Z. Li
Blockade of Tumor Necrosis Factor (TNF) Receptor Type 1-Mediated TNF-{alpha} Signaling Protected Wistar Rats from Diet-Induced Obesity and Insulin Resistance
Endocrinology, June 1, 2008; 149(6): 2943 - 2951.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Y. Donath, J. Storling, L. A. Berchtold, N. Billestrup, and T. Mandrup-Poulsen
Cytokines and {beta}-Cell Biology: from Concept to Clinical Translation
Endocr. Rev., May 1, 2008; 29(3): 334 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Lo, L. E. Bernstein, B. Canavan, M. Torriani, M. B. Jackson, R. S. Ahima, and S. K. Grinspoon
Effects of TNF-{alpha} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E102 - E109.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
I C van Eijk, M J L Peters, M T Nurmohamed, A W van Deutekom, B A C Dijkmans, and S Simsek
Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis
Eur. J. Endocrinol., March 1, 2007; 156(3): 291 - 293.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. G. Boulton and J. T. Bourne
Unstable diabetes in a patient receiving anti-TNF-{alpha} for rheumatoid arthritis
Rheumatology, January 1, 2007; 46(1): 178 - 179.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Krogh-Madsen, P. Plomgaard, K. Moller, B. Mittendorfer, and B. K. Pedersen
Influence of TNF-{alpha} and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E108 - E114.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. E. Bernstein, J. Berry, S. Kim, B. Canavan, and S. K. Grinspoon
Effects of Etanercept in Patients With the Metabolic Syndrome.
Arch Intern Med, April 24, 2006; 166(8): 902 - 908.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Plomgaard, K. Bouzakri, R. Krogh-Madsen, B. Mittendorfer, J. R. Zierath, and B. K. Pedersen
Tumor Necrosis Factor-{alpha} Induces Skeletal Muscle Insulin Resistance in Healthy Human Subjects via Inhibition of Akt Substrate 160 Phosphorylation
Diabetes, October 1, 2005; 54(10): 2939 - 2945.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D N Kiortsis, A K Mavridis, S Vasakos, S N Nikas, and A A Drosos
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis
Ann Rheum Dis, May 1, 2005; 64(5): 765 - 766.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Rotter, I. Nagaev, and U. Smith
Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-{alpha}, Overexpressed in Human Fat Cells from Insulin-resistant Subjects
J. Biol. Chem., November 14, 2003; 278(46): 45777 - 45784.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. J. Klover, T. A. Zimmers, L. G. Koniaris, and R. A. Mooney
Chronic Exposure to Interleukin-6 Causes Hepatic Insulin Resistance in Mice
Diabetes, November 1, 2003; 52(11): 2784 - 2789.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. M. Fernandez-Real and W. Ricart
Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Endocr. Rev., June 1, 2003; 24(3): 278 - 301.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
N. Sattar, C. G Perry, and J. R Petrie
Type 2 diabetes as an inflammatory disorder
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 36 - 41.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. A. Kern, S. Ranganathan, C. Li, L. Wood, and G. Ranganathan
Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
Am J Physiol Endocrinol Metab, May 1, 2001; 280(5): E745 - E751.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society